Last updated on April 2016

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Doserange- finding Trial of IW-3718 Administered Orally for 8 Weeks to Patients with Symptomatic Gastroesophageal Reflux Disease that Persists Despite Treatment with Proton Pump Inhibitors


Brief description of study

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Doserange- finding Trial of IW-3718 Administered Orally for 8 Weeks to Patients with Symptomatic Gastroesophageal Reflux Disease that Persists Despite Treatment with Proton Pump Inhibitors

Detailed Study Description

Treatment for patients with esophageal reflux, randomized in a 1:1:1:1 ratio, subject will take 3 tablets twice a day after meals

Clinical Study Identifier: TX6497

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Amanda Davis LPN

Chase Medical Research, LLC
Waterbury, CT USA
  Connect »